The Business Cocktail

The Business Cocktail

Posted on

  1. Cancer Research UK and Cancer Research Technology to collaborate with TYG Oncology
  2. GE Healthcare and Valneva collaboration results in cell culture medium for vaccine production
  3. UPS to Acquire Marken
  4. Asymchem Laboratories, Xbrane Biopharma, Biohaven Pharmaceutical Holding Company

To read more please visit :

The Business Cocktail

Pill
Blue globes from drug capsule
Advertisements

Business Cocktail

Posted on

Medivir entered into an agreement with Karo Pharma to sell its subsidiary BioPhausia

Medivir is set to sell is subsidiary, BioPhausia, to Karo Pharmafor for Skr908m ($100.9m). The agreement shows that this price will be on a cash and debt free basis, including a normalized working capital, with the transaction expected to close by mid-December. BioPhausia comprises 13 established pharmaceutical drugs. From the third quarter of 2015 to the second quarter of 2016, BioPhausia posted revenues of Skr189m ($21m).

Astellas to acquire German company Ganymed Pharmaceuticals

Japan’s Astellas Pharma has signed an agreement to acquire German-based biopharmaceutical company Ganymed Pharmaceuticals for €1.2bn. With this transaction, Astellas will be able to continue to build upon its oncology franchise as a platform for sustainable growth. Under the agreement, Astellas will initially pay €422m to acquire 100% stake in Ganymed and Ganymed’s shareholders will subsequently receive up to €860m based on progress in the IMAB362 clinical programme development.

Celldex Acquires Kolltan Pharmaceuticals

Celldex Therapeutics has entered into a definitive agreement to acquire Kolltan Pharmaceuticals, a clinical-stage company focused on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases (RTKs), primarily in oncology. Clinical data has shown that Kolltan’s drug candidates can help overcome tumor resistance mechanisms associated with current tyrosine kinase inhibitors. Celldex believes Kolltan’s drug candidates and preclinical platform are compatible with the company’s scientific approach and can be developed independently and in combination with Celldex’s existing product candidates.

Allergan to Acquire Motus Therapeutics

Further building its gastrointestinal (GI) disease portfolio, Allergan plans to acquire Motus Therapeutics (formerly Rhythm Health), the GI-focused, wholly owned subsidiary of Rhythm Holding, for $200 million upfront plus an undisclosed sales milestone payment. The acquisition is the third in 5 weeks through which Allergan has expanded its GI offerings. Allergan had previously started plans to acquire Tobira Therapeutics for $1.695 billion and Akarna Therapeutics for $50 million. This acquisition is Allergan’s third, which includes Motus’ lead drug candidate, relamorelin (RM-131), a ghrelin agonist being developed for diabetic gastroparesis.

The Business Cocktail

Posted on Updated on

Sun Pharma & ICGEB announce exclusive collaboration to develop novel dengue vaccine

International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma Ltd. announced their new collaboration for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause disease in humans. ICGEB has developed a tailored recombinant virus-like-particle (VLP) based tetravalent dengue vaccine, containing host-receptor binding domain of envelope protein of all the four DENV serotypes. ICGEB has conducted pre-clinical studies over the past seven years and developed the existing Know-How and Patents for this dengue vaccine candidate.

Boehringer Ingelheim and Lupin Sign agreement for Diabetes Drug

Drug firms Boehringer Ingelheim and Lupin have entered into a partnership to co-market Empagliflozin used for treatment of type 2 diabetes in India. Lupin will market and sell Empagliflozin under a separate brand name Gibtulio which will be promoted by Lupin’s specialty field force. Boehringer Ingelheim will continue to sell Empagliflozin under the brand name Jardiance through their existing sales force and network

Daiichi Sankyo Announces New Strategic Immuno-Oncology Research Collaboration with AgonOx

Daiichi Sankyo announced that it has entered into a strategic collaboration with AgonOx, Inc., a privately held biotechnology company developing a pipeline of novel immunotherapy drugs targeting key regulators of the immune response to cancer, to develop an undisclosed immuno-oncology target. Daiichi Sankyo and AgonOx will collaborate on preclinical development of the program. Following preclinical assessment, Daiichi Sankyo has an exclusive option to research, develop, manufacture and commercialize the program worldwide

Catalent Pharma Solutions partners with Samsung Bioepis Co. for Commercial Biosimilar supply

Catalent Pharma Solutions announced that it is to provide fill-finish production services for the commercial supply of SB4, a biosimilar referencing Enbrel® (etanercept), on behalf of the Korea-based biopharmaceutical company Samsung Bioepis Co., Ltd. The services will be provided at Catalent’s flagship sterile pre-filled syringe facility in Brussels, Belgium. SB4 is the first etanercept biosimilar to receive regulatory approval by the European Commission (EC), as Benepali.

Celltrion Healthcare and Teva enters into exclusive business collaboration agreement for Truxima™ and Herzuma™ in the U.S. and Canada

Celltrion’s commercial partner for its second and third biosimilars for the North America market has been determined. Celltrion announced that it has selected Teva Pharmaceuticals, as its exclusive commercial partner for Truxima and Herzuma in the US and Canada. Celltrion has applied for marketing authorization from the EMA last October. Mabthera (also known as Rituxan), the reference product to Truxima, was developed by Biogen and marketed by Roche.  Herzuma is a biosimilar to Herceptin, a breast cancer treatment antibody biologic drug developed by Genentech and marketed by Roche.